UBS maintains AbbVie at Neutral, raises price target to $295 from $275

What happened

UBS kept its rating on AbbVie at Neutral and raised its price target to $295 from $275, a 7.3% increase. UBS said the new target implies 2.1% upside from the November 2 closing price of $288.84.

Confirmed

Global impact / market context

The higher target signals UBS sees somewhat more value in AbbVie, but its Neutral rating and the stated 2.1% implied upside suggest limited expected gain from the cited closing price. The target may shape investor expectations, but it does not change AbbVie’s sales or costs by itself.

Analyst inference

Five other recent analyst targets listed for AbbVie range from $322 to $346, all above UBS’s $295 target. This shows UBS’s view is more cautious than those cited opinions, though analyst targets are estimates rather than guaranteed share prices.

Confirmed

What to watch

1. Compare later UBS updates with its $295 target and Neutral rating; a change in either would show whether the firm’s view of AbbVie’s expected share value has shifted. Analyst inference
2. Watch for company results or guidance that clarify sales and costs; stronger or weaker business performance could support or undermine the assumptions behind analyst price targets. Analyst inference
3. The five other cited analyst targets run from $322 to $346, while UBS’s is $295; check whether future published targets narrow or widen this gap. Confirmed

Evidence

• Original source link unavailable